An association between diabetes mellitus (DM) and pancreatic ductal adenocarcinoma (PDA) has been recognized for more than half a century,1 yet diagnostic and therapeutic applications of this relationship remain limited. Increasing epidemiologic evidence suggests that patients with DM are at significantly greater risk for PDA. In a population-based study of 2122 patients with DM, the incidence of pancreatic cancer within 3 years of DM diagnosis was nearly 8 times that of the general nondiabetic population.2
Although long-standing DM may be a risk factor for developing PDA, new-onset DM may, conversely, be a manifestation of the cancer. Patients with PDA are significantly more likely to have new-onset DM (<2-year duration) than noncancer controls3 and to have a significantly higher prevalence of DM than patients with other types of cancer, such as lung, breast, prostate, and colorectal cancers, and patients without cancer.4
Moreover, dysglycemia itself may have a negative impact on outcomes of hospitalized patients with cancer in terms of infection, mortality, length of stay, and toxicities. The risk of cancer death (from stomach, liver, lung cancers) has been noted to be significantly higher among those with a high fasting plasma glucose (≥5.6 mmol/L), after adjustment for potentially confounding factors.5
This article directly evaluates the relationship between glycosylated hemoglobin (HbA1c), an objective and quantifiable measure of glucose intolerance, and pancreatic cancer in patients without a history of chronic DM presenting with suspected PDA. Specifically, this article examines the potential utility of HbA1c level to discriminate between benign pancreatic disease (BPD) and stages of PDA, and investigates the effect of impaired glucose tolerance on patient survival outcomes.
Funding was received from National Cancer Institutes, P30 CA006973, and the Claudio X. Gonzalez Family Foundation. The authors have disclosed that they have no financial interests, arrangements, affiliations, or commercial interests with the manufacturers of any products discussed in this article or their competitors.
GreenRCJrBaggenstossAHSpragueRG. Diabetes mellitus in association with primary carcinoma of the pancreas. Diabetes1958;7:308–311.
ChariSTLeibsonVLRabeKG. Probability of pancreatic cancer following diabetes: a population-based study. Gastroenterology2005;129:504–511.
PannalaRLeirnessJBBamletWR. Prevalence and clinical profile of pancreatic cancer-associated diabetes mellitus. Gastroenterology2008;134:981–987.
AggarwalGKamadaPChariST. Prevalence of diabetes mellitus in pancreatic cancer compared to common cancers. Pancreas2013;42:198–201.
HirakawaYNinomiyaTMukaiN. Association between glucose tolerance level and cancer death in a general Japanese population: the Hisayama study. Am J Epidemiol2012;176:856–864.
QiuHWildATWangH. Comparison of conventional and 3-dimensional computed tomography against histopathologic examination in determining pancreatic adenocarcinoma tumor size: implications for radiation therapy planning. Radiother Oncol2012;104:167–172.
SenerSFFremgenAMenckHRWinchesterDP. Pancreatic cancer: a report of treatment and survival trends for 100,313 patients diagnosed from 1985-1995, using the National Cancer Database. J Am Coll Surg1999;189:1–7.
SchwartsSSZeidlerAMoossaAR. A prospective study of glucose tolerance, insulin, C-peptide, and glucagon responses in patients with pancreatic carcinoma. Am J Dig Dis1978;23:1107–1114.
DjiogueSNwabo KamdjeAHVecchioL. Insulin resistance and cancer: the role of insulin and insulin-like growth factors. Endocr Relat Cancer2013;20:R1–17.
D’EspositoVPassarettiFHammarstedtA. Adipocyte-released insulin-like growth factor-1 is regulated by glucose and fatty acids and controls breast cancer cell growth in vitro. Diabetologia2012;55:2811–2822.
WangFAdrianTEWestermarkG. Dissociated insulin and islet amyloid polypeptide secretion from isolated rat pancreatic islets cocultured with human pancreatic adenocarcinoma cells. Pancreas1999;18:403–409.
WangFLarssonJAbdiuA. Dissociated secretion of islet amyloid polypeptide and insulin in serum-free culture media conditioned by human pancreatic adenocarcinoma cell lines. Int J Pancreatol1997;21:157–164.
BassoDMillinoCGrecoE. Altered glucose metabolism and proteolysis in pancreatic cancer cell conditioned myoblasts: searching for a gene expression pattern with a microarray analysis of 5000 skeletal muscle genes. Gut2004;53:1159–1166.
ValerioABassoDBrigatoL. Glucose metabolic alterations in isolated and perfused rat hepatocytes induced by pancreatic cancer conditioned medium: a low molecular weight factor possibly involved. Biochem Biophys Res Commun1999;257:622–628.
AggarwalGRamachandranVJaveedN. Adrenomedullin is up-regulated in patients with pancreatic cancer and causes insulin resistance in β cells and mice. Gastroenterology2012;143:1510–1517.
PermertJIhseIJorfeldtL. Improved glucose metabolism after subtotal pancreatectomy for pancreatic cancer. Br J Surg1993;80:1047–1050.
PermertJAdrianTEJacobssonP. Is profound peripheral insulin resistance in patients with pancreatic cancer caused by a tumor-associated factor?Am J Surg1993;165:61–66discussion 66-67.
StoreySVon AhD. Impact of malglycemia on clinical outcomes in hospitalized patients with cancer: a review of the literature. Oncol Nurs Forum2012;39:458–465.
DecensiAPuntoniMGoodwinP. Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis. Cancer Prev Res (Phila)2010;3:1451–1461.